한빛사 논문
Se-Hoon Lee1,2,15, Sung-Yup Cho3,4,15, Youngmin Yoon5,15, Changho Park6,15, Jinyoung Sohn6, Jin-Ju Jeong6, Bu-Nam Jeon6, Mongjoo Jang6, Choa An6, Suro Lee6, Yun Yeon Kim6, Gihyeon Kim5, Sujeong Kim5, Yunjae Kim5, Gwang Bin Lee7, Eun Ju Lee6, Sang Gyun Kim6, Hong Sook Kim1, Yeongmin Kim5, Hyun Kim5, Hyun-Suk Yang8, Sarang Kim8, Seonggon Kim9, Hayung Chung10, Myeong Hee Moon7, Myung Hee Nam10, Jee Young Kwon11, Sungho Won12, Joon-Suk Park9,16, George M. Weinstock11,16, Charles Lee11,13,14,16, Kyoung Wan Yoon6,8,* and Hansoo Park5,6,*
1Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University School of Medicine, Seoul, Korea. 3Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. 4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 5Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea. 6Genome and Company, Gyeonggi-do, Korea. 7Department of Chemistry, Yonsei University, Seoul, Korea. 8Department of Biotechnology, Hoseo University, Asan, Korea. 9Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu, Korea. 10Korea Basic Science Institute, Seoul Center, Seoul, Korea. 11The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. 12Department of Public Health Sciences, Seoul National University, Seoul, Korea. 13Department of Life Science, Ewha Womans University, Seoul, Korea. 14The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China. 15These authors contributed equally: Se-Hoon Lee, Sung-Yup Cho, Youngmin Yoon and Changho Park. 16These authors jointly supervised this work: Joon-Suk Park, George M. Weinstock and Charles Lee.
*Correspondence to Kyoung Wan Yoon or Hansoo Park.
Abstract
The gut microbiome can influence the development of tumours and the efficacy of cancer therapeutics1,2,3,4,5; however, the multi-omics characteristics of antitumour bacterial strains have not been fully elucidated. In this study, we integrated metagenomics, genomics and transcriptomics of bacteria, and analyses of mouse intestinal transcriptome and serum metabolome data to reveal an additional mechanism by which bacteria determine the efficacy of cancer therapeutics. In gut microbiome analyses of 96 samples from patients with non-small-cell lung cancer, Bifidobacterium bifidum was abundant in patients responsive to therapy. However, when we treated syngeneic mouse tumours with commercial strains of B. bifidum to establish relevance for potential therapeutic uses, only specific B. bifidum strains reduced tumour burden synergistically with PD-1 blockade or oxaliplatin treatment by eliciting an antitumour host immune response. In mice, these strains induced tuning of the immunological background by potentiating the production of interferon-γ, probably through the enhanced biosynthesis of immune-stimulating molecules and metabolites.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기